Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating safety and immunogenicity of revaccination with PPV23 in adults aged 60-70 years has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease
• Pneumococcal Infection

Drugs mentioned

• PPV23 (pneumococcal polysaccharide vaccine)

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: Vaccination | Phase 4 | Status: COMPLETED